Stephen Poor

Stephen Poor

Company: Novartis AG

Job title: Director - External Innovation & Translational Biomarkers

Seminars:

Panel Discussion: Working Around Clinical Trial Challenges for Retinal Vascular Disease Drug Development 1:30 pm

Discussing challenges of getting the next generation of therapeutics approved for DME and nAMD Highlighting the novel end points beyond BCVA to establish meaningful differentiation from VEGF therapy Overcoming challenges with regulators and payers to get approval and funding for therapiesRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.